TMEM164

Across TCGA pan-cancer cohorts, TMEM164 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM164 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TMEM164 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM164 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LUAD, and UCEC are the cancer types where TMEM164 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.165	0.541	.004	18	view →
LUAD	OS	Median	All	0.090	0.788	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.931	0.433	.013	14	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM164–OV (DFS)

Open the OV breakdown →